Abstract: Reflector antennas and related methods are disclosed. An example antenna includes a base; a first rib and a second rib, the first rib and the second rib moveable relative to the base; a reflective material carried by the first rib and the second rib, the first rib, the second rib, and the reflective material to define a reflector portion of the antenna; and a gold-plated clip to couple a portion of the reflective material to the first rib.

Abstract: Reflector antennas and related methods are disclosed. An example antenna includes a hub; ribs coupled to the hub; a reflective material; gold-plated clips to couple the reflective material to respective ones of the ribs; and an actuator to cause respective ones of the ribs to move relative to the hub from a folded position to an unfolded position to expand the reflective material.

Abstract: The present invention provides a compound of Formula I. or a pharmaceutically acceptable salt thereof, and the use of compounds of Formula I for treating metabolic conditions, such as type 2 diabetes mellitus, heart failure, diabetic kidney disease, and non-alcoholic steatohepatitis.

Abstract: The present invention provides a compound of Formula (I), or a pharmaceutically acceptable salt thereof, and the use of compounds of Formula (I) for treating metabolic conditions, such as type 2 diabetes mellitus, heart failure, diabetic kidney disease, and non-alcoholic steatohepatitis.

Abstract: The present invention provides a compound of Formula I. or a pharmaceutically acceptable salt thereof, and the use of compounds of Formula I for treating metabolic conditions, such as type 2 diabetes mellitus, heart failure, diabetic kidney disease, and non-alcoholic steatohepatitis.

Abstract: Provided is a method of treating and/or preventing Wolfram Syndrome (WS)-related neurodegeneration (i.e. of Wolfram Syndrome-Associated Neuronal Degeneration), by increasing the expression and/or functional activity of p21. A method of screening for pharmacological agents useful in treating and/or preventing such conditions is also provided.

Abstract: The present invention provides a compound of Formula I or a pharmaceutically acceptable salt thereof, and the use of compounds of Formula I for treating metabolic conditions, such as type 2 diabetes mellitus, heart failure, diabetic kidney disease, and non-alcoholic steatohepatitis.

Abstract: The present invention provides a compound of Formula I or a pharmaceutically acceptable salt thereof, and the use of compounds of Formula I for treating metabolic conditions, such as type 2 diabetes mellitus, heart failure, diabetic kidney disease, and non-alcoholic steatohepatitis.

Abstract: The present invention provides a compound of Formula I: or a pharmaceutically acceptable salt thereof, and the use of compounds of Formula I for treating metabolic conditions, such as type 2 diabetes mellitus, heart failure, diabetic kidney disease, and non-alcoholic steatohepatitis.

Abstract: The present invention provides a compound of Formula I: or a pharmaceutically acceptable salt thereof, and the use of compounds of Formula I for treating metabolic conditions, such as type 2 diabetes mellitus, heart failure, diabetic kidney disease, and non-alcoholic steatohepatitis.

Abstract: An intermediary access device enables a user electronic device to communicate with a vehicle's onboard computer system. A first wireless transceiver of the intermediary access device is used to establish a secure wireless communication channel between the intermediary access device and a vehicle on-board computer system. A second wireless transceiver of the intermediary access device is used to establish a user-initiated communication channel between the intermediary access device and a user electronic device. User commands and vehicle information can then be transmitted between the vehicle on-board computer system and the user electronic device via the intermediary access device in a safe, secure and efficient manner.

Abstract: 1-Oxo-1,2-dihydroisoquinolin-7-yl-(5-substituted-thiophen-2-yl)-sulfonamide compounds, formulations containing those compounds, and their use as AICARFT inhibitors.

Abstract: 1-Oxo-1,2-dihydroisoquinolin-7-yl-(5-substituted-thiophen-2-yl)-sulfonamide compounds, formulations containing those compounds, and their use as AICARFT inhibitors.

Abstract: The present invention provides compounds having the formula: wherein R1 is selected from methyl, ethyl, propyl, cyclopropyl, and dimethyl, or a pharmaceutically acceptable salt thereof, along with methods and intermediates for their preparation, and uses thereof.

Abstract: Provided is a method of treating and/or preventing Wolfram Syndrome (WS)-related neurodegeneration (i.e. of Wolfram Syndrome-Associated Neuronal Degeneration), by increasing the expression and/or functional activity of p21. A method of screening for pharmacological agents useful in treating and/or preventing such conditions is also provided.

Abstract: The present invention provides compounds having the formula: wherein R1 is selected from methyl, ethyl, propyl, cyclopropyl, and dimethyl, or a pharmaceutically acceptable salt thereof, along with methods and intermediates for their preparation, and uses thereof.

Abstract: An intermediary access device enables a user electronic device to communicate with a vehicle's onboard computer system. A first wireless transceiver of the intermediary access device is used to establish a secure wireless communication channel between the intermediary access device and a vehicle on-board computer system. A second wireless transceiver of the intermediary access device is used to establish a user-initiated communication channel between the intermediary access device and a user electronic device. User commands and vehicle information can then be transmitted between the vehicle on-board computer system and the user electronic device via the intermediary access device in a safe, secure and efficient manner.

Abstract: A steam autoclave (steam sterilization system) has a door for opening and closing an opening that defines the entrance to and exit from a steam sterilization chamber. The door may be latched and locked and pneumatically sealed when in a closed position. Preferably, the door has a convex portion that projects into the sterilization chamber when the door is in a closed position for aiding in providing an even distribution of steam throughout the sterilization chamber during operation of the steam autoclave.

Abstract: A steam autoclave for treating Regulated Medical Waste that uses a condensate drainage system that provides for condensate drainage while the steam autoclave chamber remains pressurized during the steam treatment cycle to create pressure variations in the autoclave which are used to initiate the introduction of repeated bursts of steam into the waste during the steam treatment cycle. The repeated bursts of steam into the autoclave during the steam treatment cycle agitates the steam and waste contained in the autoclave, thereby enhancing steam penetration into the waste being treated and thereby enhancing biological kill efficacy.

Abstract: A system and method for content exclusion from a multi-domain search, where search results are prioritized or potentially excluded based on content provided by a service provider. The system and method provide for providing access to a network by a primary service provider, the network including multiple sources of content; receiving at least one search parameter; performing a search for content based on the received at least one search parameter; prioritizing results of the search based on content provided by the primary service provider; and displaying the prioritized results. In one embodiment, the system and method further includes excluding at least one search result if the at least one search result matches content provided by the primary service provider.